Claims from The Gambia regarding possibly lethal Indian-made cough syrups prompted India’s Central Drugs Standard Control Organization (CDSCO), the country’s drug regulator, to conduct statewide risk-based inspections in 2022 and 2023. As a result of the inadequate manufacturing standards identified in numerous plants, the CDSCO has ordered 76 out of 237 pharmaceutical companies to halt production. Following the WHO and Gambia’s claims, the United States, Indonesia, Uzbekistan, the Marshall Islands, Micronesia, and the Gambia all expressed concerns about the quality of Indian drugs… Click Here to Read Full
Share this:
- Click to share on WhatsApp (Opens in new window)
- Click to share on Facebook (Opens in new window)
- Click to share on X (Opens in new window)
- Click to share on Pinterest (Opens in new window)
- Click to share on Twitter (Opens in new window)
- Click to share on Tumblr (Opens in new window)
- Click to share on Mastodon (Opens in new window)
- Click to share on Reddit (Opens in new window)
- Click to email a link to a friend (Opens in new window)
- Click to share on LinkedIn (Opens in new window)
- Click to print (Opens in new window)
- Click to share on Telegram (Opens in new window)
- Click to share on Pocket (Opens in new window)
- Click to share on Nextdoor (Opens in new window)
- More
Related
Discover more from The Gambia Journal
Subscribe to get the latest posts sent to your email.